metallothionein1

Metallothionein 1 (MT1) is a low‑molecular‑weight, cysteine‑rich protein that binds heavy metals such as zinc, copper and cadmium. It belongs to the metallothionein family, which is conserved across mammals, birds, fish and invertebrates. In humans, the MT1 gene cluster is located on chromosome 16p13.3 and comprises several highly homologous genes (MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1I, MT1J, MT1K, MT1L, MT1M, MT1X). Transcription of these genes is regulated by metal ions, oxidative stress, glucocorticoids, cytokines and growth factors through metal‑responsive elements and NF‑κB binding sites.

The MT1 protein is 61 to 68 amino acids long and contains 20–21 cysteine residues that coordinate up to eight metal ions. The high cysteine content gives it a unique capacity to form metal‑thiolate clusters, facilitating intracellular metal homeostasis, detoxification and protection against oxidative damage. Metallothionein 1 also plays a role in the regulation of metal‑dependent enzymes, intracellular signaling pathways, and cellular proliferation.

MT1 expression is highly inducible. Exposure to cadmium, zinc, or arsenic induces robust upregulation, providing rapid protection against metal toxicity. In human tissues, MT1 is most abundant in liver, kidney, and bone, but is also found in brain, lung and immune cells. In addition, it is constitutively expressed at low levels in erythrocytes and spermatozoa, shielding them from metal‑induced oxidative stress.

Clinical associations of MT1 include modulation of carcinogenesis, where overexpression can confer resistance to chemotherapy and promote invasion in breast, prostate and colorectal cancers. Conversely, reduced MT1 levels have been linked to increased susceptibility to metal‑induced neurotoxicity and impaired wound healing. Polymorphisms within the MT1 gene cluster influence individual responses to environmental metals and may predispose to disorders such as Wilson disease, porphyria, and certain autoimmune diseases.

Research on MT1 also explores its therapeutic potential. Synthetic peptides mimicking MT1 sequences offer protective effects in models of acute kidney injury, sepsis and radiation damage. Ongoing studies aim to clarify its regulatory networks and to develop MT1‑based biomarkers for metal toxicity and oxidative stress.